Biotech Booster and CSL have taken a significant step towards accelerating biotech innovations. The organizations signed a collaboration agreement to combine their strengths, expertise, and network to help projects bring their biotech innovations to market as fast as possible.
Since its inception, Biotech Booster has supported over 50 early-stage biotech projects across The Netherlands. These projects are led by pioneering researchers working on groundbreaking solutions in fields ranging from oncology and immunology to diagnostics and cell therapy. With more projects in the pipeline, Biotech Booster continues to gain momentum as a national hub for biotech innovation.
To amplify this impact, Biotech Booster is expanding its network of international collaborations. “We are proud that CSL is joining as our first corporate partner, marking a big milestone in our efforts to bridge the gap between innovation and global industry expertise”, says Nettie Buitelaar, CEO at Biotech Booster. “CSL is a renowned global biotechnology leader that brings scientific and commercial knowledge in areas such as autoimmune diseases, hematology, transplant, cardiovascular diseases, nephrology, immunoglobulins and vaccines. Just like us, CSL is driven by a commitment to innovation that improves lives. Thanks to this collaboration, projects can tap into the knowledge and the vast network that CSL provides, helping them to develop their innovations further.”
Through this non-exclusive partnership, Biotech Booster and CSL will work side-by-side, providing guidance and feedback to selected projects to help unlock their full potential.
“The Netherlands continues to emerge as a dynamic life sciences hub, backed by a vibrant venture capital landscape, globally impactful academic research, and an innovation ecosystem anchored by leading science parks in Leiden, Amsterdam, and Utrecht,” says Marthe D’Ombrain, Executive Director & Head Research External Innovation, CSL. “The Dutch Biotech Booster offers a unique platform to foster new biotech ventures, and CSL’s partnership complements our broader efforts to support and source promising biotech opportunities across Europe and drive scientific breakthroughs.”
In the near future, the management teams of both organizations will come together to officially kick off the collaboration.
